QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS

QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS

November 29, 2021

  • Additional U.S. approval for LIAISON® XS platform builds on FDA approval in 2019 for QuantiFERON assay running on DiaSorin’s LIAISON® XL analyzer
  • Collaboration now provides full range of automation platforms for TB testing options to customers, ranging from small healthcare clinics to larger hospitals and reference laboratories
  • QIAGEN’s QuantiFERON Interferon Gamma Release Assay (IGRA) technology the leading assay for detection of latent TB with high clinical sensitivity

HILDEN, Germany & SALUGGIA, Italy–(BUSINESS WIRE)– QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced that the U.S. Food and Drug Administration (FDA) has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.

The approval widens the accessibility of U.S. customers to automation solutions for processing QIAGEN’s leading blood-based test for latent tuberculosis (TB) detection and support the conversion from the traditional tuberculin skin tests that were developed over a century ago.

The highly automated workflow on LIAISON® platforms gives QuantiFERON® customers a powerful, flexible automated option for all throughput ranges. The addition of the fully automated LIAISON® XS platform to the already approved use of this assay on the LIAISON®XL version expands the range of potential customers to include experts at smaller healthcare clinics alongside those at larger hospitals and medical centers and reference laboratories. Read More

Comments are closed.